3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
2
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
2
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
17
Radiotherapy
8
pembrolizumab
7
Radiotherapy, Intensity-Modulated
7
Fluorouracil
7
Magnetic Resonance Spectroscopy
6
Docetaxel
6
Platinum
5
Gemcitabine
5
1,2-diaminocyclohexaneplatinum II citrate
5
Paclitaxel
4
Specimen Handling
3
Radiation
3
Drug Therapy
3
Cetuximab
3
Carboplatin
3
(225)Ac-DOTA-c(RGDyK)
3
atezolizumab
2
Iodine-123
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
Disulfides
2
Biopsy
2
trametinib
1
toripalimab
1
ponatinib
1
pertuzumab
1
nimotuzumab
1
fosbretabulin
1
fluorocholine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Vemurafenib
×
Head & Neck
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled